Teva Drug Would Infringe Mylan Patent, Judge Says

Law360, New York (July 17, 2013, 7:18 PM ET) -- A West Virginia federal judge ruled Wednesday that an treatment proposed by generic drugmaker Teva Pharmaceutical USA Inc. would violate a patent covering Mylan Inc.'s respiratory illness drug Perforomist.

U.S. District Judge Irene M. Keeley said Teva's generic form of Perforomist violates two asserted claims in U.S. Patent Number 6,667,344, held by Mylan Specialty, a subsidiary of Mylan that specializes in manufacturing drugs that treat respiratory diseases.

The '344 patent is one of four patents-in-suit covering Perforomist that will be asserted at an upcoming trial before...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required